Abstract
Trials, registries and guidelines for non-ST-elevation acute coronary syndromes
Highlights
The most common admission indication in cardiology practice is acute coronary syndrome with or without ST-segment elevation
The only important side effect of dual antiplatelet therapy is increased bleeding in comparison with aspirin alone
The novel platelet P2Y12 receptor antagonists prasugrel and ticagrelor are more effective than clopidogrel in patients, but show more major bleeding including intracranial haemorrhage [15, 16]
Summary
The most common admission indication in cardiology practice is acute coronary syndrome with or without ST-segment elevation. The cornerstone of the treatment of patients undergoing coronary stenting for acute coronary syndromes is dual antiplatelet therapy with aspirin and the platelet P2Y12 receptor antagonist clopidogrel. Many patients in cardiology practice in 2013 are on dual antiplatelet therapy, mainly aspirin and clopidogrel. The only important side effect of dual antiplatelet therapy is increased bleeding in comparison with aspirin alone.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
